Nano cap Immuron Limited (NASDAQ:IMRN) jumps 118% premarket on robust volume in reaction to its announcement that IMM-124E, hyperimmune bovine antibodies used to make immune supplements Travelan and Protectyn, showed neutralizing activity against SARS-CoV-2 in cell-based assays.
Certain concentrations of IMM-124E inhibited viral replication by 90% with no signs of toxicity to cells.
CEO Jerry Kanellos, Ph.D. says the encouraging data warrants “further evaluation” for its potential use in COVID-19.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.